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T-CELL RECEPTOR, NORMALLY
T-cell receptors reside on the surface of T-cells, and recognize a
specific antigen presented by an MHC molecule
Next, the T-cells become either CD4 or CD8 cells
Co-stimulation is a key step in activating the T-cell; B7 proteins on
the surface of antigen-presenting cells interact with CD28/CTLA-4
receptors on the T-cell.

HOW TUMOR CELLS EVADE IMMUNITY
Tumor cells have mechanisms to take advantage of the immune
system's intrinsic ability to overcome autoimmunity, hiding from the
immune system and avoiding destruction. One of these
mechanisms is the hijacking of immune-cell-intrinsic checkpoints
that are induced on T-cell activation. These checkpoints include the
cytotoxic T-lymphocyte-associated antigen, CTLA-4, whose ligand,
B7/CD80 is upregulated on tumor cells. Another inhibitory T-cell
receptor is the programmed death 1 receptor, PD-1R, whose
ligands PD-L1 and PD-L2 are expressed on tumor cells.

DOWNREGULATION OF PD-1R OR ITS LIGAND
A novel treatment for metastatic melanoma takes advantage of this
PD-1 receptor and its ligand that directly deliver immune suppressive
signals. Anti-PD-1 and anti-PD-L1 monoclonal antibodies are used to
prevent the inhibition of T-cells that can then go on to eliminate tumor
cells. Two antibodies have been studied: nivolumab (anti-PD-1R
and lambrolizumab (anti-PD-1R).

A COMPARISON TO PREDECESSORS
INHIBITION

WHAT IS THE T-CELL’S JOB?
T-cells are upregulated in chronic inflammatory states, and
cytotoxic T-cells recognize and destroy virally infected cells and
tumor cells, Normally, a type of antigen-presenting cells, called
dendritic cells, bring information about invaders to the T-cells, and
using co-stimulator molecules such as B7, influence T-cells to
respond appropriately to the invader. Dendritic cells play a role in
orchestrating response to certain cancers. T-cells are trained at an
early stage to avoid responding to “self” antigens, a process called
immune tolerance.

PD-1 RECEPTOR AND PD-1 LIGAND
PD-1 inhibitory receptor is expressed by T-cells during long-term
antigen exposure and results in negative regulation upon ligation
with PD-1 and 2 ligands. This interaction occurs primarily in
inflamed tissues and the tumor microenvironment. PD-1R:PD-1L
interactions maintain peripheral tolerance, and are exploited by
tumors to evade immune eradication.

IMMUNE-CHECKPOINT

PD-1 is an immune-checkpoint
receptor expressed by activated Tcells, functioning mainly in
peripheral tissues where T-cells
encounter tumor and stromal cells.
TUMOR MARKERS SERVING AS TREATMENT TARGETS
Her2neu is an abnormal and over-expressed neoantigen in certain
tumor cells, namely in Her2+ breast cancers. Trastuzumab is a
monoclonal antibody that targets Her2 and kills the expressing cell.
Vascular endothelial growth factor is a normal protein that is overexpressed in various tumors. Bevacizumab attaches to this protein and
prevents formation of new blood vessels in the tumor

WHY THIS WILL “CHANGE THE GAME”
PD-1 and PD-L1 antibodies have been named “Drug of the Year” by
theEuropean Journal of Cancer. The highly tumor-selective immune
suppressive signals, along with PD-1 regulation primarily in the effector
phase of T-cell response, have allowed for decreased side effects and
improved anti-tumor activity compared to CTLA-4 inhibition. Anti-PD1
and anti-PDL1 have broken the previous ceiling of durable tumor
response rates of 10-15%, and have yielded responses in advanced
melanoma, refractory non-small cell lung cancer, and renal cancer.
It has shown anti-tumor activity in liver, lung, lymph node, and bone
metastases.
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